文献速递头颈部肿瘤放疗

头颈部鳞状细胞癌放化疗后三个月FDG-PET/CT可使相当数量患者免于挽救性颈清扫

FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection.
PubMed 文献 · Radiother Oncol · 2024-06-26

本研究纳入2008至2022年间908例淋巴结阳性头颈部鳞状细胞癌患者,评估FDG-PET/CT联合标准诊断(MRI+超声引导细针穿刺)对挽救性颈清扫患者选择的准确性。FDG-PET/CT对病理确诊残留颈淋巴结病变的阳性预测值为89%,高于MRI+超声引导细针穿刺的65%;代谢完全缓解患者未行挽救性颈清扫,阴性预测值97.5%。

要点

  • FDG-PET/CT对病理确诊残留颈淋巴结病变的阳性预测值为89%,MRI+超声引导细针穿刺为65%。
  • 代谢完全缓解患者未行挽救性颈清扫,阴性预测值97.5%,仅2.5%出现延迟区域失败。
  • 第二研究期较第一研究期挽救性颈清扫标本中活肿瘤比例显著更高(53% vs 31%,p=0.008)。

核心结论

  • 将FDG-PET/CT纳入放化疗后反应评估诊断路径,显著提高了挽救性颈清扫患者选择的准确性,并使相当数量(>20%)患者免于不必要的挽救性颈清扫。
  • 对于代谢完全缓解患者,可安全省略挽救性颈清扫;对于无代谢完全缓解患者,强烈主张行挽救性颈清扫。

研究设计与样本

  • 2008年至2022年间在本机构连续纳入908例淋巴结阳性头颈部鳞状细胞癌患者,均接受放化疗。
  • 主要终点为FDG-PET/CT对挽救性颈清扫后病理确诊残留颈淋巴结病变的阳性预测值,对照标准诊疗MRI+超声引导细针穿刺;次要终点为肿瘤学结局。

主要发现

  • 全组130例(14%)接受挽救性颈清扫,其中仅53例(41%)在挽救性颈清扫标本中病理确诊残留颈淋巴结病变。
  • FDG-PET/CT检测病理确诊残留颈淋巴结病变的阳性预测值为89%,MRI+超声引导细针穿刺为65%。
  • FDG-PET/CT显示代谢完全缓解的患者未行挽救性颈清扫,阴性预测值为97.5%,仅2.5%出现延迟区域失败。
  • 第二研究期较第一研究期(各454例)挽救性颈清扫标本中仍有活肿瘤的比例显著更高(53% vs 31%,p=0.008)。
  • 病理确诊残留颈淋巴结病变患者的区域无复发生存、无病生存、总生存及头颈部鳞状细胞癌死亡均显著更差(p<0.05)。

关键数值与推荐

  • FDG-PET/CT对病理确诊残留颈淋巴结病变的阳性预测值为89%,MRI+超声引导细针穿刺为65%。
  • FDG-PET/CT显示代谢完全缓解患者未行挽救性颈清扫,阴性预测值为97.5%,延迟区域失败率为2.5%。
  • 第二研究期较第一研究期挽救性颈清扫标本中活肿瘤比例显著更高(53% vs 31%,p=0.008)。

临床怎么用

  • 作者结论认为,将FDG-PET/CT纳入放化疗后反应评估诊断路径可提高挽救性颈清扫患者选择准确性,并使相当数量(>20%)患者免于不必要的挽救性颈清扫。
  • 作者结论认为,对于代谢完全缓解患者可安全省略挽救性颈清扫,对于无代谢完全缓解患者强烈主张行挽救性颈清扫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the last decades FDG-PET/CT is increasingly used in combination with the standard diagnostic modalities (MRI + US-FNA) to identify residual neck disease (RND) after (chemo)radiotherapy for head-and-neck squamous cell carcinoma (HNSCC). The purpose of the current study is to identify the impact of increasing use of FDG-PET/CT on the accuracy of patient selection for salvage neck dissection (SND). MATERIALS AND METHODS: Between 2008 and 2022, 908 consecutive patients with node-positive HNSCC were treated with (chemo)radiotherapy in our institution. PRIMARY ENDPOINT: positive predictive value (PPV) of FDG-PET/CT for pathologic-confirmed RND (pRND) after SND, compared to the standard of care; MRI + US-FNA. Secondary endpoints: oncologic outcomes. RESULTS: Of the entire group, 130 patients (14 %) received SND. Of them only 53 patients (41 %) had pRND at the SND-specimens. The PPV of FDG-PET/CT for the detection of pRND was considerably better, compared to MRI + US-FNA; 89 % and 65 %, respectively. If FDG-PET/CT showed metabolic CR, these patients did not undergo SND. The NPV was 97.5 %, as only 2.5 % of these patients developed delayed regional failure. FDG-PET/CT considerably improved the accuracy of patient selection for SND, as significantly more patients treated in the second period, compared to first period of the study (n = 454 each) still had vital tumor at SND-specimen (53 % and 31 %, p = 0.008). Regional recurrence free-survival, DFS, OS and HNSCC-death were significantly worse in patients with pRND (p < 0.05) CONCLUSIONS: Incorporating FDG-PET/CT into the diagnostic pathway for the response evaluation after (chemo)radiotherapy significantly improved the accuracy of patient selection for SND and spared considerable number of patients (>20 %) from unnecessary SND. For patients with metabolic CR, SND can safely be omitted while for patients with no metabolic CR, SND is strongly advocated.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Navran A, Kayembe MT, Gouw ZAR, et al. FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection. Radiother Oncol. 2024. PMID: 38942119. doi:10.1016/j.radonc.2024.110407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。